ClinicalTrials.gg

Program

Dronabinol

Also written as “Dronabinol Oral Solution”, “GW-2000-02” and “SP-104”.

Its studies are mostly in Pain · Fasting · Vomiting · Sleep Apnea, Obstructive · Cancer Pain, led by 14 companies.

Furthest: phase 3, since Oct 5, 201120 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
INSYS Therapeutics30 open or runningphase 1since Oct 5, 2011Oct 5, 2011none ahead
Jazz Pharmaceuticals30 open or runningphase 3since Apr 28, 2008Apr 28, 2008none ahead
Abbott20 open or runningphase 3since Mar 21, 2008Mar 21, 2008none ahead
Scilex Pharmaceuticals20 open or runningphase 1since Jul 6, 2021Jul 6, 2021none ahead
Benuvia Therapeutics11 open or runningphase 3since Feb 11, 2026Feb 11, 2026May 30, 2028phase 3 · NCT07422311
bionorica-research-gmbh10 open or runningphase 3since Aug 13, 2009Aug 13, 2009none ahead
CannaXan10 open or runningphase 1since Feb 24, 2022Feb 24, 2022none ahead
daisy-pharma-opioid-venture-llc10 open or runningphase 2since Nov 30, 2018Nov 30, 2018none ahead
FG Brasil LTDA10 open or runningphase 3since Mar 8, 2022Mar 8, 2022none ahead
Incannex Healthcare11 open or runningphase 2since Jun 3, 2026Jun 3, 2026Apr 2027phase 2 · NCT07635563
Par Health10 open or runningphase 1since Jun 16, 2011Jun 16, 2011none ahead
scisparc10 open or runningphase 2since Aug 9, 2018Aug 9, 2018none ahead
Sobereye10 open or runningno phasesince Apr 14, 2025Apr 14, 2025none ahead
ZYUS Life Sciences10 open or runningphase 2since Jul 25, 2024Jul 25, 2024none ahead

Also a collaborator on its studies: KGK Science and fgk-clinical-research-gmbh.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Mar 21, 2008.

  1. Oct 5, 2011INSYS Therapeutics's first study: phase 1 study in FastingNew to INSYS TherapeuticsINSYS Therapeutics · NCT01448772 · 88 enrolled · United States
  2. May 23, 2012Phase 3 study in PainJazz Pharmaceuticals · NCT01606189 · 48 enrolled · United Kingdom
  3. Mar 14, 2014Phase 1 study in Substance-Related DisordersINSYS Therapeutics · NCT02094599 · 43 enrolled · Canada
  4. Nov 12, 2015No phase study in HealthyINSYS Therapeutics · NCT02604992 · 54 enrolled · United States
  5. Aug 9, 2018scisparc's first study: phase 2 study in Tourette SyndromeNew to scisparcscisparc · NCT03651726 · 60 enrolled · Germany
  6. Nov 30, 2018daisy-pharma-opioid-venture-llc's first study: phase 2 study in Chronic PainNew to daisy-pharma-opioid-venture-llcdaisy-pharma-opioid-venture-llc · NCT03766269 · 280 enrolled · United States
  7. Jul 6, 2021Scilex Pharmaceuticals's first study: phase 1 study in Healthy VolunteersNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT04958876 · 52 enrolled · New Zealand
  8. Aug 5, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT05002946 · 18 enrolled · New Zealand
  9. Feb 24, 2022CannaXan's first study: phase 1 study in Marijuana AbuseNew to CannaXanCannaXan · NCT05267769 · 12 enrolled · Germany
  10. Mar 8, 2022FG Brasil LTDA's first study: phase 3 study in FibromyalgiaNew to FG Brasil LTDAFG Brasil LTDA · NCT05283161 · 40 enrolled
  11. Jul 25, 2024ZYUS Life Sciences's first study: phase 2 study in Cancer PainNew to ZYUS Life SciencesZYUS Life Sciences · NCT06533657 · 11 enrolled · Canada
  12. Apr 14, 2025Sobereye's first study: no phase study in Cannabis IntoxicationNew to SobereyeSobereye · NCT06967051 · 20 enrolled · Canada
  13. Feb 11, 2026Benuvia Therapeutics's first study: phase 3 study in Aberrant Motor Behavior in DementiaNew to Benuvia TherapeuticsBenuvia Therapeutics · NCT07422311 · 140 planned · Australia
  14. Jun 3, 2026Incannex Healthcare's first study: phase 2 study in Sleep Apnea, ObstructiveNew to Incannex HealthcareIncannex Healthcare · NCT07635563 · 120 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Sleep Apnea, ObstructiveIncannex Healthcare · NCT07635563
  2. May 30, 2028Primary completion: phase 3 study in Aberrant Motor Behavior in DementiaBenuvia Therapeutics · NCT07422311

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor agonist”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
CannabidiolruleJazz Pharmaceuticalsphase 468
RimonabantruleSanofiphase 338
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07635563Sleep Apnea, Obstructive · United States2RecruitingIncannex HealthcareApr 2027120
NCT07422311Aberrant Motor Behavior in Dementia · Australia3Not yet recruitingBenuvia TherapeuticsMay 30, 2028140
NCT06967051Cannabis Intoxication · Canada–CompletedSobereyeAug 19, 202520
NCT06533657Cancer Pain · Canada2CompletedZYUS Life SciencesApr 15, 202611
NCT05283161Fibromyalgia3UNKNOWNFG Brasil LTDAAug 20, 202240
NCT05267769Marijuana Abuse · Germany1CompletedCannaXanApr 3, 202212
NCT05002946Healthy · New Zealand1CompletedScilex PharmaceuticalsApr 24, 202218
NCT04958876Healthy Volunteers · New Zealand1CompletedScilex PharmaceuticalsDec 20, 202152
NCT03766269Chronic Pain · United States2UNKNOWNdaisy-pharma-opioid-venture-llcJun 1, 2019280
NCT03651726Tourette Syndrome · Germany2UNKNOWNscisparcNov 201960
NCT02604992Healthy · United States–CompletedINSYS TherapeuticsDec 201554
NCT02094599Substance-Related Disorders · Canada1CompletedINSYS TherapeuticsMay 201443
NCT01606189Pain · United Kingdom3CompletedJazz PharmaceuticalsSep 200248
NCT01448772Fasting · United States1CompletedINSYS TherapeuticsDec 201188
NCT01380457Fasting · United States1CompletedPar HealthApr 200669
NCT00959218Multiple Sclerosis · Germany3Completedbionorica-research-gmbhMar 2010240
NCT00675948Pain · United Kingdom3CompletedJazz PharmaceuticalsSep 200643
NCT00674609Pain · United Kingdom3CompletedJazz PharmaceuticalsFeb 2004177
NCT00642512Vomiting · United States3CompletedAbbottJul 200464
NCT00642499Vomiting · United States2CompletedAbbottApr 2005103

How it is read

Names in the registry

  • “Dronabinol”, 4 entries
  • “Dronabinol Oral Solution”, 2 entries
  • “GW-2000-02”, 2 entries
  • “SP-104”, 2 entries
  • “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry

Codes read as this program: GW200002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.